CA
NZ
UK
AU
IND
US
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares traded at $25.09, down 1.99% on the day, after the FDA granted Fast Track designation to remlifanserin, also known as ACP-204, under the RADIANT trial program for Alzheimer's disease psychosis.
Immunome Inc. (NASDAQ: IMNM) shares traded at $22.16, down 0.72% on the day, after the company disclosed that Phase 1 dosing has commenced for its immunotherapy candidate 177Lu-IM-3050.
Dogwood Therapeutics Inc. (NASDAQ: DWTX) shares traded at $1.38, unchanged on the day, after the company completed enrollment in its Phase 2b HALT-CINP trial evaluating Halneuron for chemotherapy-induced neuropathic pain.
BioLineRx Ltd. (NASDAQ: BLRX) shares traded at $2.83, down 2.41% on the day, as the company continues to advance GLIX1 in glioblastoma, with Phase 1/2 dosing underway.
Dyne Therapeutics Inc. (NASDAQ: DYN) shares traded at $23.45, down 1.22% on the day, as the company's zeleciment rostudirsen, also known as z-rostudirsen or DYNE-251, awaits a Priority Review PDUFA date of January 21, 2027, in the DELIVER trial program.
Scholar Rock Holding Corporation (NASDAQ: SRRK) shares traded at $50.66, down 4.16% on the day, as the company continues to advance two late-stage programs: SRK-181 in solid tumors and apitegromab in spinal muscular atrophy.
REGENXBIO Inc. (NASDAQ: RGNX) shares traded at $10.32, up 4.35% on the day, after the company reported Phase 2 ALTITUDE trial data for RGX-314 in diabetic retinopathy.
Oncolytics Biotech Inc. (NASDAQ: ONCY) shares traded at $0.85, down 0.39% on the day, after the FDA granted fast-track designation to the company's GOBLET trial, evaluating pelareorep and mFOLFIRINOX with and without atezolizumab in colorectal and advanced anal cancers.
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) shares traded at $11.09, up 0.91% on the day, after the company shared two-year Phase 2b PRISM trial data for 4D-150 in wet age-related macular degeneration (AMD) at the ASRS meeting.
PolyPid Ltd. (NASDAQ: PYPD) shares fell approximately 8% despite the company forming an exclusive commercial alliance with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX100, aimed at preventing abdominal surgical site infections (SSIs).
Please wait processing your request...